The clinical observations of deleterious TLR7 variants and a poor type I IFN response found in 1–2% across male cohorts of severe cases identify TLR7 as an important PRR in the immune response against COVID-19, especially in younger patients. This evidence concerns the gene TLR7 and COVID-19.